Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

COVID-19: Which Drug, When, and Why? Monoclonal Antibody Treatments
  • CME

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: April 15, 2022 Expiration: April 14, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.
Gregory Huhn, MD, MPHTM

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate findings from evolving data on individual classes of COVID-19 therapies into optimized treatment plans now and in the future

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Gregory Huhn, MD, MPHTM

Associate Professor
Department of Infectious Diseases
Rush University Medical Center
Senior Director of HIV Services
Department of Infectious Diseases
Cook County Health
Chicago, Illinois

Gregory Huhn, MD, MPHTM, has disclosed that he has received funds for research support from Lilly and consulting fees from Gilead Sciences, Janssen, and ViiV.

Staff

Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine Seeskin, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals involved in the management of COVID-19 patients in both inpatient and outpatient settings. This identified target audience will benefit from this education by gaining the knowledge and strategies necessary to individualize COVID-19 management across the spectrum of disease.

Goal

The goal of this activity is to improve learners’ competence in prescribing the most appropriate agent or combination at the optimal time, based on disease pathogenesis and treatment characteristics and modes of action.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category I Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours .05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-110-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 15, 2022, through April 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

COVID-19: Which Drug, When, and Why? Monoclonal Antibody Treatments
  • CME

Loading...
Hear expert insights on the role and timing of monoclonal antibody treatments for COVID-19, including specific considerations related to omicron and its subvariants.
Gregory Huhn, MD, MPHTM
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: April 15, 2022 Expiration: April 14, 2023

Related Content

Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)

Megan Coffee, MD, PhD (DPhil) Released: June 2, 2022

Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Renslow Sherer, MD Released: June 1, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings